Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc

Marissa J.M. Traets; Kathelijn Fischer; Nanda Uitslager; Paul R. van der Valk; Idske C.L. Kremer Hovinga; Lize F.D. van Vulpen; Roger E.G. Schutgens

doi:10.1055/s-0040-1718416

TH Open, Table of Contents

CC BY 4.0 · TH Open 2020; 04(04): e362-e364
DOI: 10.1055/s-0040-1718416

Letter to the Editor

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc

Marissa J.M. Traets

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Kathelijn Fischer

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Nanda Uitslager

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Paul R. van der Valk

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Idske C.L. Kremer Hovinga

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Lize F.D. van Vulpen

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

,

Roger E.G. Schutgens

¹Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands

› Author Affiliations

Abstract

Full Text

References

References
1 Mahlangu J, Powell JS, Ragni MV. A-LONG Investigators. et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (03) 317-325
2 Powell JS, Pasi KJ, Ragni MV. B-LONG Investigators. et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
3 Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S. Association of Hemophilia Centre Directors of Canada (AHCDC). Switching to extended half-life products in Canada - preliminary data. Haemophilia 2017; 23 (04) e365-e367
4 Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia 2018; 24 (03) 414-419
5 Carcao M, Zunino L, Young NL. et al. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool. Haemophilia 2020; 26 (01) 73-78
6 Iorio A, Keepanasseril A, Foster G. WAPPS-Hemo co-investigator network. et al. Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-hemo): study protocol. JMIR Res Protoc 2016; 5 (04) e239
7 Fischer K, Kulkarni R, Nolan B. et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol 2017; 4 (02) e75-e82